bluuebunny/crossref_metadata_2025_split huggingface dataset:
P1725Current spectrum and 1-year mortality of cardiogenic shock in Europe. Results of the CULPRIT-SHOCK randomized clinical trial and registry
Authors: Zeymer U , Desch S , Ouarrak T , Akin I , De Waha-Thiele S , Montalescot G , Piek J J , Huber K , Thiele H 
Published: October 2019

Abstract

Background
An early invasive strategy with coronary revascularization has been shown to improve prognosis in patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS). Little is known about the current spectrum, treatment and 1-year mortality in patients with CS undergoing early angiography in Europe.

Methods
We evaluated baseline characteristics, treatments and 1-year outcome in a large number of patients with CS included into the prospective CULPRIT-SHOCK randomized trial and the accompanying registry. Between April 2013 and April 2017, a total of 1075 patients with cardiogenic shock were screened at 83 European centers, of whom 706 (65.6%) were included in the randomized trial RCTand 369 into the registry.

Results
The median age was 67 years and 25% were female. In total, 55% of patients had pre-hospital resuscitation, 6% underwent fibrinolysis before angiography, 65% presented with ST-elevation myocardial infarction, 15% with left bundle branch block, and 20% with non-ST-elevation myocardial infarction. The majority of patients (80%) needed mechanical ventilation. Catecholamines were used in 90% and mechanical support in 29.5% of the patients (IABP 38.5%, ECMO 22%, Impella 33%, other 7%). Total 30-day and 1-year mortality was 46% and 52%, respectively. Mechanical complications were observed in 2.1% of patients, the latter had a 30-day and 1-year mortality of 62% and 67%, respectively. The mortality related to the extent of coronary artery disease is shown in the table.
1-vessel (14%) 2-vessel (31%) 3-vessel (55%) Left main (15%) 30-day mortality 36% 44% 51% 53% 1-year mortality 39% 50% 57% 64%

Conclusions
This first report including data of the prospective CULPRIT-SHOCK randomized trial as well as the accompanying registry demonstrates the high-risk clinical characteristics of patients with AMI complicated by CS undergoing contemporary treatment. Despite an early invasive strategy mortality in patients with AMI complicated by CS in Europe is still high and is related to the extent of coronary artery disease.
P1736A novel calcium parameter, calcium ratio, can predict minimum lumen area in calcified lesions: optical coherence tomographic study
Authors: Matsuhiro Y , Nisino M , Nakamura H , Yasumoto K , Tanaka A , Nakamura D , Matsunaga Y , Yano M , Yamato M , Egami Y , Syutta R , Tanouti J 
Published: October 2019

Abstract

Background
Several reports have revealed that minimum lumen area (MLA) is associated with target lesion failure even with newer-generation drug-eluting stents, and calcified lesions usually induced inadequate lumen area because of stent under expansion. Contemporary debulking devices such as rotational/orbital atherectomy can modify severe calcified lesions before stenting. However, there are no optimal criteria to indicate necessity for calcium modification to obtain adequate acute gain. Therefore, we investigated useful calcium parameters correlating with MLA in the calcified lesions after stenting.

Methods
We enrolled 71 consecutive calcified lesions (71 patients) who underwent optical coherence tomography (OCT) guided percutaneous coronary intervention (PCI) between September 2016 and January 2019. Exclusion criteria included acute coronary syndrome, in-stent restenosis and lesions without any calcium or treated with rotational atherectomy. If there were several calcium lesions in one patient, we selected maximum calcium angle lesion. We compared mean reference area, pre lumen area and various calcium parameters including calcium arc, maximum thickness, depth, area, longitudinal length and calcium ratio that was maximum calcium thickness divided by nearest reference diameter in disease-free segments as much as possible in pre-PCI OCT evaluation with post-PCI lumen area at that site by simple and multiple regression analysis.

Results
Calcium ratio was an independent predictor for post-PCI lumen area in addition to mean reference area, while the others were not associated with post-PCI lumen area (table).
Results of OCT parameters Univariate analysis Multivariate analysis P value P value β Mean reference area <0.01 <0.01 0.69 Pre lumen area <0.01 0.08 0.15 Cacium arc <0.01 0.58 −0.06 Calcium maximum thickness 0.62 Calcium ratio <0.01 0.01 −0.21 Calcium area 0.02 0.64 0.05 Calcium longitudinal length 0.60 Calcium depth 0.09

Conclusion
The novel calcium measurement, calcium ratio, may be a useful predictor for post-PCI lumen area for calcified lesions.
P1781Burden of significant valvular heart disease in elderly patients presenting with acute coronary syndromes
Authors: Montalto C , Crimi G , Fortuni F , Mandurino Mirizzi A , Ferri L A , Morici N , Tortorella G , Grosseto D , Sganzerla P , Ferrario M , Savonitto S , De Servi S 
Published: October 2019

Abstract

Background
Elderly patients with acute coronary syndromes (ACS) represent a group seldom included in clinical trials and in whom robust data regarding mid-term impact of significant concomitant valvular heart disease are lacking.

Purpose
Our aim was to evaluate the impact of moderate-to-severe mitral regurgitation (MR), moderate-to-severe aortic stenosis (AS), or both conditions combined on a primary composite endpoint of mortality, myocardial infarction, disabling stroke and re-hospitalization for cardiovascular causes or bleeding within one year in a population of ACS patients included in the Elderly ACS 2 trial.

Methods
In the multicenter Elderly II ACS Study, 1,443 patients aged >74 y undergoing percutaneous coronary intervention (PCI) for ACS, were randomly assigned to receive prasugrel (5 mg) or clopidogrel (75 mg) and were prospectively followed for 1 year. Amongst these, 1,102 patients received full echocardiographic assessment and were included in the post-hoc analysis (Table 1).

Results
Survival analysis showed that patients presenting with moderate-to-severe MR, AS or both (Figure 1A), had worse outcome in terms of primary endpoint (p<0.001) as compared to no valve disease. A multivariable Cox regression model revealed that the presence of moderate-to-severe MR, AS or both were independent predictors of primary endpoint (HR 1.84; HR 2.8; HR 2.9 and p<0.001; p=0.004; p=0.01, respectively), regardless of age, gender, left ventricular ejection fraction, diabetes mellitus, history of cancer and total number of diseased vessels (Figure 1B).
Table 1 Overall No residual valvular heart disease Moderate-to-severe MR Moderate-to-severe AS Both Age (y) 80.68±4.50 80.40±4.42 81.47±4.45 82.92±5.42 83.23±5.42 Male gender 652 (59.2) 538 (61.6) 92 (48.4) 19 (73.1) 3 (23.1) STE-ACS 420 (38.1) 319 (36.5) 91 (47.9) 6 (23.1) 4 (30.8) Diabetes mellitus 203 (18.4) 158 (18.1) 35 (18.4) 5 (19.2) 5 (38.5) LVEF (%) 48.30±9.58 49.26±9.27 44.61±9.45 48.50±11.22 38.31±10.87 History of cancer 32 (2.9) 26 (3.0) 3 (1.6) 2 (7.7) 1 (7.7) Tot number of diseased vessel 2.31±1.05 2.28±1.04 2.49±1.05 2.04±0.87 2.54±1.13 Data are expressed as mean ± SD or count (valid %).
Figure 1

Conclusions
Moderate-to-severe MR and AS represent significant predictors of 1-year outcome in elderly patients hospitalized for ACS, even when other well-established prognostic factors are taken into account and after revascularization with PCI. Therefore, these patients should be carefully screened for the presence of valvular heart disease at the time of presentation and the need for surgical or percutaneous correction should be assessed accordingly.

Acknowledgement/Funding
None
P1783Prognostic implications of significant tricuspid regurgitation in patients with atrial fibrillation in the absence of left-sided heart disease or pulmonary hypertension
Authors: Dietz M F , Prihadi E A , Van Der Bijl P , Ajmone Marsan N , Delgado V , Bax J J 
Published: October 2019

Abstract

Background
Tricuspid regurgitation (TR) can be caused by atrial fibrillation (AF) in the absence of left-sided heart disease or pulmonary hypertension. The prognostic impact of AF-TR has not been investigated.

Purpose
The aim of this study was to investigate the prognostic significance of TR in AF patients who do not show left-sided heart disease, pulmonary hypertension or primary structural abnormalities.

Methods
A total of 63 AF patients with moderate and severe TR were identified and matched by age and gender to 116 patients with AF without significant TR, resulting in a total study population of 179 patients (mean age 71±7 years, 59% male). As per design of the study, patients with primary TR, significant (moderate or severe) aortic and/or mitral valve disease, previous valvular surgery, congenital heart disease, left ventricular ejection fraction <50%, systolic pulmonary artery pressure >40mmHg, pacemaker or implantable cardioverter defibrillator leads in situ were excluded as well as patients with AF de novo. Patients were followed for the combined endpoint of all-cause mortality, hospitalization for heart failure and stroke.

Results
Patients with AF-TR had more often paroxysmal AF as compared to patients without TR (60% vs. 43%, p=0.028). In addition, right atrial volumes and the tricuspid annulus diameter (TAD) were significantly larger in patients with AF-TR compared to their counterparts (p<0.001 for all). Furthermore, tricuspid annular plane systolic excursion was significantly lower in patients with AF-TR (17±5 mm vs. 21±6 mm, p<0.001). During follow-up (median 62 [32–95] months) 55 events for the combined endpoint occurred. One- and 5-year event-free survival rates for patients with TR were 71% and 53%, compared to 92% and 85% for patients without TR, respectively (Log rank Chi-Square p<0.001; Figure). In the multivariable Cox proportional hazard model adjusted for age, gender, NYHA functional class >2, renal function, right ventricular (RV) function and TAD, the presence of significant TR was independently associated with the combined endpoint (HR, 2.495; 95% CI, 1.167–5.335; p=0.018), while RV function was not (HR, 1.026; 95% CI, 0.971–1.085; p=0.364).
Figure 1. Kaplan-Meier curves

Conclusion
In the absence of left-sided heart disease and pulmonary hypertension, significant TR is independently associated with worse event-free survival in patients with AF.
P1818Descending aortic thoracic diameter: a risk marker for major adverse cardiovascular outcomes in women
Authors: Rueda Ochoa O L , Bons L R , Rohde S , Ghoud K E L , Budde R , Ikram M K , Deckers J W , Vernooij M W , Franco O H , Van Der Lugt A , Roos-Hesselink J W , Bos D , Kavousi M 
Published: October 2019

Abstract

Background
Thoracic aortic diameters have been associated with cardiovascular risk factors and atherosclerosis. However, limited evidence regarding the role of thoracic aortic diameters as risk markers for major cardiovascular outcomes among women and men exist.

Purpose
To evaluate the independent associations between crude and indexed ascending and descending aortic (AA and DA) diameters with major cardiovascular outcomes among women and men and to provide optimal cutoff values associated with increased cardiovascular risk.

Methods and results
2178 women and men ≥55 years from the prospective population-based Rotterdam Study underwent multi-detector CT scan of thorax. Crude diameters of the AA and DA were measured and indexed by height, weight, body surface area (BSA) and body mass index (BMI). Incidence of stroke, coronary heart disease (CHD), heart failure (HF), cardiovascular and all-cause mortality were evaluated during 13 years of follow-up.
Weight-, BSA-, or BMI-indexed AA diameters showed significant associations with total or cardiovascular mortality in both sexes and height-indexed values showed association with HF in women. Crude AA diameters were associated with stroke in men and HF in women. For DA, crude and almost all indexed diameters showed significant associations with either stroke, HF, cardiovascular or total mortality in women. Only weight-, BSA- and BMI-indexed values were associated with total mortality in men. For crude DA diameter, the risk for stroke increased significantly at the 75th percentile among men while the risks for HF and cardiovascular mortality increased at the 75th and 85th percentiles respectively in women.

Conclusions
Our study suggests a role for descending thoracic aortic diameter as a marker for increased cardiovascular risk, in particular for stroke, heart failure and cardiovascular mortality among women. The cut points for increased risk for several of cardiovascular outcomes were below the 95th percentile of the distribution of aortic diameters.
P1823Aortic walls elastic properties assessment with ultrafast ultrasound imaging in case of bicuspid aortic valve
Authors: Goudot G , Mirault T , Cheng C , Gruest M , Amoah J , Pedreira O , Khider L , Pernot M , Messas E 
Published: October 2019

Abstract

Background
Magnetic resonance imaging allows evaluation of aortic stiffness by the maximum rate of systolic distension (MRSD) a new prognosis factor of aortic dilatation in patients with bicuspid aortic valve (BAV). MRSD requires a continuous monitoring of the aortic diameter during the cardiac cycle, not accessible to conventional echocardiography contrary to ultrafast ultrasound imaging (UF).

Purpose
To develop specific aortic sequences in ultrafast ultrasound imaging (UF) to provide access to the aortic MRSD

Methods
Tissue Doppler allowed a precise estimation of the movement of each wall and the fine variation of the aortic diameter. To automatically track the anterior and posterior aortic walls during the cardiac cycle, we developed in the laboratory a specific interface (Figure). MRSD was the maximum of the derivative of the diameter chande over time. To assess this new technique, 24 patients (10 BAV patients and 14 controls, mean age 45.8 vs. 40.7 years, p=0.464, respectively) were consecutively included at a reference center for BAV. The ascending aorta was evaluated at the sinus of Valsalva, the tubular aorta and the aortic arch with a phased array probe (Supersonic Imagine) and dedicated sequences at 2000 frames/s.

Results
The lab-made interface allowed to track the aortic diameter and to calculate the MRSD from the UF acquisitions for each patient. We found lower MRSD at the sinus of Valsalva in case of BAV in accordance with previously demonstrated higher stiffness at this segment by our team (Table).
Table 1. UF Aortic parameters for BAV patients and controls BAV patients Controls p (Mann Whitney) Sinus of Valsalva Diameter (mm) 26.2 [22.4–32.5] 27.09 [23.5–29.5] 0.796 MRSD (s–1) 1.05 [0.73–1.19] 1.51 [1.28–1.99] 0.023 Tubular ascending aorta Diameter 31.4 [29.4–32.2] 28.9 [22.6–31.5] 0.328 MRSD 0.94 [0.59–1.27] 1.09 [0.87–1.41] 0.353 Aortic arch Diameter 24.2 [23.7–24.8] 24.2 [18.9–24.5] 0.673 MRSD 0.57 [0.35–1.07] 0.85 [0.76–1.02] 0.257 Results are median [25th–75th percentile].
Figure 1

Conclusion
UF allows evaluation of aortic stiffness by MRSD using dedicated sequence and interface. As echocardiography, UF is easily accessible and therefore deserves attention from cardiologists taking care of BAV patients to evaluate the segmental aortic remodeling associated with BAV.
P1902Comparison of efficacy of different anticoagulation strategies used during pulmonary vein isolation in left atrial blood samples
Authors: Hajas O , Bagoly Z S , Toth N K , Sarkady F , Kovacs K B , Kappelmayer J , Csiba L , Csanadi Z 
Published: October 2019

Abstract

Introduction
Ablation of atrial fibrillation is based on the isolation of the pulmonary veins (PVI) from the left atrium. Cerebral thromboembolism is a rare but serious complication of PVI, which highlights the importance of peri-procedural anticoagulation.

Aim
Studying the coagulation and endothelium activation during PVI in case of using different anticoagulation protocols.

Method
52 patients undergoing PVI with cryoballoon technique were involved and were grouped according to three different pre-procedural anticoagulation strategies: in the first group patients received no anticoagulation before the procedure (non anticoag., 24 patients)-, in the second group patients received uninterrupted vitamin K antagonist therapy, and their INR value was in therapeutic range on the day of the procedure (VKA group, 11 patients) and in the third group patients were on uninterrupted dabigatran therapy (dabigatran group, 17 patients).
Two blood samples were taken during PVI from the left atrium, the first one before ablation or iv. heparin administration, the second one directly after the last application at the end of the procedure. The samples were used to measure D-dimer, plasmin antiplasmin (PAP) complex, a2 plasmin inhibitor (a2PI), plasminogen, FVIII activity, von Willebrand factor (VWF) antigen levels.

Results
D-dimer levels increased in all three groups after ablation, but in the samples of patients on dabigatran therapy we detected significantly lower D-dimer levels in the pre- and post-procedural samples compared to patients on other therapeutic strategies (median values before or after PVI: non anticoag.: 0.48 and 1.09 mgFEU/L; VKA: 0.33 and 0.72 mgFEU/L, dabigatran: 0.12 and 0.30 mgFEU/L, p<0.001 non anticoag. vs. dabigatran, p<0.01 VKA vs. dabigatran). PAP complex values were increasing parallel with D-dimer levels and only in the dabigatran group did not increase significantly. VWF antigen and FVIII activity increased significantly in all three groups after ablation, but there was no significant difference between the groups.

Conclusions
the safest anticoagulation strategy for patients undergoing PVI was uninterrupted dabigatran therapy. The extend of endothelial damage was not affected by anticoagulation.
P1909Cryobaloon pulmonary vein isolation without pulmonary venography
Authors: Mengel C , Lee X W , Betts J , Ingram R , Haqqani H M 
Published: October 2019

Abstract

Introduction
Cryoballoon pulmonary vein isolation (PVI) has been shown to be non-inferior to radiofrequency PVI and have several advantages including shorter procedure times. Cryoballoon PVI traditionally requires the use of occlusive pulmonary venography to assess for balloon position and contact however, some patients have contraindications to the use of iodinated radiocontrast.

Purpose
We assessed the feasibility of performing cryoballoon PVI without pulmonary venography.

Methods
Thirty-five initial consecutive patients with paroxysmal or persistent atrial fibrillation underwent cryoballoon PVI as a primary procedure under conscious sedation by a single operator. None had a contraindication to radiocontrast administration. Left atrial CT was obtained the day prior in all patients to assess pulmonary vein anatomy. Transeptal puncture was performed using 1–5 ml of contrast given the non-routine availability of intracardiac echocardiography. CT images obviated the requirement for pre-balloon deployment venography and pulmonary vein balloon occlusion was assessed by tactile feedback as well as the fluoroscopic appearance of balloon deformation (Fig 1.). If adequate temperature was not obtained with initial cooling during ablation, application was discontinued and the balloon repositioned. If repeated ablation did not result in sufficient cooling and vein isolation, pulmonary venography was utilised to assess adequacy of vein occlusion and sites of leak.

Results
The median age was 57 yrs with 69% male and 63% having paroxysmal AF. 137/138 pulmonary veins were successfully isolated with mean 1.77 ablations per vein. Median nadir ablation temperature was −45°C (range −62 to −30°C) with a median time to isolation of 36.5 seconds. 120/138 (87%) of veins were isolated without the use of contrast, however 18/138 required venography. Overall, 63% of patients had successful PVI without requiring any pulmonary venography. Average procedure time was 104 minutes. One patient sustained a mediastinal hematoma that resolved with conservative management. Median follow up was 3.6 months, with 74% of patients being free from atrial fibrillation at last follow up.

Conclusion
This study demonstrates that it is feasible to perform cryoballoon PVI without pulmonary venography in 87% of targeted veins. In this series, 63% of patients had successful 4 vein isolation without pulmonary vein contrast administration. This technique combined with imaging guided transeptal puncture can allow for truly contrast-less PVI in patients with severe contrast allergy or severe renal dysfunction.
P1929A randomized controlled trial evaluating outcome impact of cilostazol in patients with coronary artery disease and at a high risk of cardiovascular disease
Authors: Chao T.-H , Tseng S.-Y , Liu P.-Y , Li Y.-H 
Published: October 2019

Abstract

Background
We and others have previously found that cilostazol has a favorable effect on glucose and lipid homeostasis, endothelial function, anti-atherosclerosis, and vasculo-angiogenesis. However, it is poorly understood that if this compound can provide better clinical outcome.

Purpose
This study investigated the outcome effect of cilostazol in patients with coronary artery disease (CAD) or at a high risk of cardiovascular (CV) disease.

Methods
We conducted a randomized, double-blind, placebo controlled trial involving 266 patients to receive cilostazol 200 mg/day (n=134) or dummy placebo (n=132). The primary endpoint was a composite of CV death, non-fatal myocardial infarct, non-fatal stroke, hospitalization for congestive heart failure or unplanned coronary revascularization. Pre-specified secondary endpoints include the composite major coronary event (MCE) and major adverse CV and cerebrovascular event (MACCE) on long-term follow-up. The mean duration of follow-up was 2.9 years.

Results
Relative to placebo, cilostazol treatment had a borderline effect on risk reduction in the primary endpoint (hazard ratio [HR], 0.67; 95% confidence interval (CI), 0.34–1.33), whereas the beneficial effect in favor of cilostazol was significant in patients with diabetes mellitus or a history of percutaneous coronary intervention (P for interaction, 0.02 and 0.06, respectively). Use of cilostazol, but not placebo, significantly reduced the risk of the MCE (HR, 0.38; 95% CI, 0.17–0.86) and MACCE (HR, 0.47; 95% CI, 0.23–0.96). A significantly lower risk of angina pectoris (HR, 0.38; 95% CI, 0.17–0.86) and unplanned revascularization (HR, 0.13; 95% CI, 0.02–1.09) was also observed in the cilostazol group. After multi-variable adjustment, cilostazol treatment independently predicted a lower risk of the MCE and MACCE.

Conclusions
Cilostazol treatment significantly reduced the risk of CV events in patients with CAD or at a high risk of CV disease.

Acknowledgement/Funding
MOST 106-2314-B-006-044, MOHW106-TDU-B-211-113003, MOHW107-TDU-B-211-113003, and MOST107-2314-B-006-076-MY2